{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/a4c5de36-8260-4222-8e38-ff997dc73436/67c09042cabc05e91c5a9139?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Rolls Royce, banking stocks and Smith & Nephew: The Companies and Markets Show","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9b44742e856e989985776/1740673011571-1d81d711-7e87-4404-a648-6a8c299d02c7.jpeg?height=200","description":"<p>Market darling <strong>Rolls Royce (RR) </strong>is going from strength to strength. After a return to dividends topped with a lucrative buyback, shares were up 20 per cent on the day of recording. James Norrington, author of <a href=\"https://www.investorschronicle.co.uk/content/69cc2a93-1844-5a0f-aa77-d1cb233d294a\" rel=\"noopener noreferrer\" target=\"_blank\">this Rolls-Royce Deep Dive</a>, unpacks the prospects for the business and everything investors need to know.&nbsp;</p><p><br></p><p><a href=\"https://www.investorschronicle.co.uk/content/df13b0c9-b8d6-566b-905c-686453d13fd8\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Smith &amp; Nephew (SN)</strong></a>, a medical equipment manufacturer, continues to improve operating performance. Mark Robinson and Julian Hofmann discuss the company and also touch on what’s going well for med-tech business <a href=\"https://www.investorschronicle.co.uk/content/d490c4b5-de00-5edc-b073-17fd74b33959\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Uniphar (UPR)</strong></a>.</p><p><br></p><p>Last but not least, Jemma Slingo unpacks our latest Big Read on banks. It hasn’t been a huge season for guidance upgrades, but there are still positives for the year. Listen to find out more.</p><p><br></p><p><strong>Timestamps</strong></p><p>1:29 Rolls Royce</p><p>10:37 Smith &amp; Nephew</p><p>19:15 Banks</p><p><br></p><p>Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit&nbsp;<a href=\"http://www.investorschronicle.co.uk/podcasttrial\" rel=\"noopener noreferrer\" target=\"_blank\">www.investorschronicle.co.uk/podcasttrial</a>&nbsp;</p><p>*After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.</p>","author_name":"Investors' Chronicle"}